» Articles » PMID: 35918332

Regulation of Cholesterol Homeostasis in Health and Diseases: from Mechanisms to Targeted Therapeutics

Overview
Date 2022 Aug 2
PMID 35918332
Authors
Affiliations
Soon will be listed here.
Abstract

Disturbed cholesterol homeostasis plays critical roles in the development of multiple diseases, such as cardiovascular diseases (CVD), neurodegenerative diseases and cancers, particularly the CVD in which the accumulation of lipids (mainly the cholesteryl esters) within macrophage/foam cells underneath the endothelial layer drives the formation of atherosclerotic lesions eventually. More and more studies have shown that lowering cholesterol level, especially low-density lipoprotein cholesterol level, protects cardiovascular system and prevents cardiovascular events effectively. Maintaining cholesterol homeostasis is determined by cholesterol biosynthesis, uptake, efflux, transport, storage, utilization, and/or excretion. All the processes should be precisely controlled by the multiple regulatory pathways. Based on the regulation of cholesterol homeostasis, many interventions have been developed to lower cholesterol by inhibiting cholesterol biosynthesis and uptake or enhancing cholesterol utilization and excretion. Herein, we summarize the historical review and research events, the current understandings of the molecular pathways playing key roles in regulating cholesterol homeostasis, and the cholesterol-lowering interventions in clinics or in preclinical studies as well as new cholesterol-lowering targets and their clinical advances. More importantly, we review and discuss the benefits of those interventions for the treatment of multiple diseases including atherosclerotic cardiovascular diseases, obesity, diabetes, nonalcoholic fatty liver disease, cancer, neurodegenerative diseases, osteoporosis and virus infection.

Citing Articles

Crossbreeding Simmental with Mongolian, and Holstein cattle can improve feed efficiency and energy metabolism by upregulating COX3 and downregulating PRSS2 gene expression.

Wu Y, Zhao P, Li X, Huangfu M, Chen Z, Wang C Front Nutr. 2025; 12:1524242.

PMID: 40062232 PMC: 11885146. DOI: 10.3389/fnut.2025.1524242.


Reducing LDL-Cholesterol to Very Low Levels: Sailing Between Established Benefits and Potential Risks.

Di Fusco S, Volpe M, Nardi F, Matteucci A, Aquilani S, Marino G High Blood Press Cardiovasc Prev. 2025; 32(2):139-149.

PMID: 39998740 DOI: 10.1007/s40292-025-00708-x.


M6A methyltransferase METTL3 promotes glucose metabolism hub gene expression and induces metabolic dysfunction-associated steatotic liver disease (MASLD).

Wang S, Xu Z, Wang Z, Yi X, Wu J BMC Genomics. 2025; 26(1):188.

PMID: 39994526 PMC: 11853331. DOI: 10.1186/s12864-025-11377-4.


Swimming exercise induces redox-lipid crosstalk to ameliorate osteoarthritis progression.

Wu Y, Hou M, Deng Y, Xia X, Liu Y, Yu J Redox Biol. 2025; 81:103535.

PMID: 39952199 PMC: 11875157. DOI: 10.1016/j.redox.2025.103535.


Cholesterol metabolism and its implications in psychotic disorders: a comparative study of individuals at ultra high risk and control groups.

Moreno M, Singulani M, van de Bilt M, Loch A, Gattaz W, Talib L Eur Arch Psychiatry Clin Neurosci. 2025; .

PMID: 39945822 DOI: 10.1007/s00406-025-01966-5.


References
1.
Ou H, Lee W, Lee I, Chiu T, Tsai K, Lin C . Ginkgo biloba extract attenuates oxLDL-induced oxidative functional damages in endothelial cells. J Appl Physiol (1985). 2009; 106(5):1674-85. DOI: 10.1152/japplphysiol.91415.2008. View

2.
CASTELLI W, Anderson K, Wilson P, Levy D . Lipids and risk of coronary heart disease. The Framingham Study. Ann Epidemiol. 1992; 2(1-2):23-8. DOI: 10.1016/1047-2797(92)90033-m. View

3.
Wu Z, McGoogan J . Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020; 323(13):1239-1242. DOI: 10.1001/jama.2020.2648. View

4.
Tosi M, Tugnoli V . Cholesteryl esters in malignancy. Clin Chim Acta. 2005; 359(1-2):27-45. DOI: 10.1016/j.cccn.2005.04.003. View

5.
. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA. 1984; 251(3):351-64. DOI: 10.1001/jama.1984.03340270029025. View